S Yonemitsu, H Nishimura, M Shintani, R Inoue, Y … - Diabetes, 2001 - Am Diabetes Assoc A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a
pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease
in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal ... Cited by 82 - Related articles - BL Direct - All 4 versions
C Kausch, J Krützfeldt, A Witke, A Rettig, O … - … and Biophysical Research …, 2001 - Elsevier To determine the immediate effect of thiazolidinediones on human skeletal muscle, differentiated
human myotubes were acutely (1 day) and myoblasts chronically (during the differentiation
process) treated with troglitazone (TGZ). Chronic TGZ treatment resulted in loss of the ... Cited by 50 - Related articles - BL Direct - All 5 versions
BS Cha, TP Ciaraldi, L Carter, SE Nikoulina, S … - Diabetologia, 2001 - Springer Skeletal muscle is the principal tissue for insulin-me- diated glucose disposal and a major site
of peripheral insulin resistance in patients with Type II (non-insu- lin-dependent) diabetes mellitus
[1, 2]. The thiazol- idinedione family of antidiabetic agents have proven effective at ... Cited by 67 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org M Shintani, H Nishimura, S Yonemitsu, Y Ogawa, T … - Diabetes, 2001 - Am Diabetes Assoc Thiazolidinediones, insulin-sensitizing agents, have been reported to increase glucose uptake
along with the expression of glucose transporters in adipocytes and cardiomyocytes.
Recently, we have further suggested that the translocation of GLUT4 is stimulated by ... Cited by 18 - Related articles - BL Direct - All 4 versions
- ►endojournals.org KS Park, TP Ciaraldi, L Abrams-Carter, S … - Journal of Clinical …, 1998 - Endocrine Soc To determine the effects of troglitazone on abnormal skeletal muscle glucose metabolism, muscle
cultures from type II diabetic patients were grown for 4–6 weeks and then fused for 4 days either
without or with troglitazone (1–5 µg/mL; chronic studies) or had troglitazone added for 90 ... Cited by 70 - Related articles - BL Direct - All 4 versions
M Loviscach, N Rehman, L Carter, S Mudaliar, P … - Diabetologia, 2000 - Springer The PPARa protein is expressed in several human tissues, including skeletal muscle, liver, kidney
and vascular endothelial cells [3]. It has been suggested that it is involved in the control of lipoprotein
metab- olism [4, 5], fatty acid oxidation [6, 7] and the cellular uptake of fatty acids [8]. The ... Cited by 104 - Related articles - BL Direct - All 3 versions
- ►endojournals.org C Nugent, JB Prins, JP Whitehead, D Savage, … - Molecular …, 2001 - Endocrine Soc Pharmacological agonists for the nuclear receptor PPAR enhance glucose disposal in a variety
of insulin-resistant states in humans and animals. The precise mechanisms whereby activation
of PPAR leads to increased glucose uptake in metabolically active cells remain to be ... Cited by 50 - Related articles - BL Direct - All 3 versions
- ►endojournals.org JR Zierath, JW Ryder, T Doebber, J Woods, M Wu, J … - Endocrinology, 1998 - Endocrine Soc Thiazolidinedione (TZD) insulin sensitizers are specific agonists of peroxisome proliferator activated
receptor (PPAR) . However, their mechanism of action and the in vivo target tissue(s) that mediate
insulin sensitization remain poorly defined. Although PPAR messenger RNA expression ... Cited by 97 - Related articles - BL Direct - All 3 versions
TP Ciaraldi, K Huber-Knudsen, M Hickman, JM … - Metabolism, clinical and …, 1995 - cat.inist.fr The antidiabetic agent troglitazone(CS-045) and a metabolite designated M 3 have potent blood
glucose-lowering actions. The mechanism of the hypoglycemic effects of troglitazone and M
3 was investigated in cultured L 6 muscle cells. Short-term(2-hour) exposure of fully ... Cited by 53 - Related articles - BL Direct - All 2 versions
AM Sironi, S Vichi, A Gastaldelli, N Pecori, R … - Clinical Pharmacology & …, 1997 - nature.com Results: By day 56, fasting plasma glucose had risen from 12.0 0.9 to 12.8 1.2 mmol/L in the
placebo group and had fallen from 12.4 0.6 to 11.3 0.6 mmol/L in the troglitazone group (p =
0.03). This was the result of small improvements in whole-body insulin sensitivity (steady- ... Cited by 44 - Related articles - BL Direct - All 5 versions
